Designing Solutions Discovering Biology Delivering Hope

ZielBio is a clinical-stage company using groundbreaking technology that reveals actionable insights to develop new therapeutic modalities to meaningfully improve patients’ lives.
A man and woman walk forward together holding hands. They are smiling and looking into each other’s eyes.

Reimagining drug discovery

Using our proprietary drug discovery platform, ZielBio identifies druggable and specific targets that have the potential to radically change how we treat disease. Learn more about our targets.
A man and woman walk forward together holding hands. They are smiling and looking into each other’s eyes.

Innovative therapies for novel disease targets

With new targets come new possibilities to transform the future of medicine and patient care. We are advancing several therapeutics to expand treatment options for patients with cancer and other serious diseases. Learn more about our therapies.

Hope for patients in need

We are currently recruiting people with certain solid tumor cancers for a Phase 1/2 clinical trial evaluating our lead investigational program, ZB131. Find out if you may be eligible.

News and resources

Latest news from ZielBio
January 03, 2023

ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics

READ MORE
December 23, 2022

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Pancreatic Cancer

READ MORE
November 15, 2022

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Cholangiocarcinoma

READ MORE
April 12, 2022

ZielBio to Present New Data Demonstrating Preclinical Efficacy of ZB131 in Cholangiocarcinoma at AACR Annual Meeting 2022

READ MORE